Journal of the Neurological Sciences
Volume 206, Issue 1 , Page 1 , 15 January 2003

Cholinesterase inhibitors: More than one function in AD?

  • J Blass

      Affiliations

    • Corresponding Author InformationTel.: +1-914-597-2356; fax: +1-914-597-2757.

Received 8 August 2002

References 

  1. Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, et al.  A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology. 2001;57:481–488
  2. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, et al.  A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001;57:489–495
  3. Henke CJ, Burchmore MJ. The economic impact of tacrine in the treatment of Alzheimer's disease. Clin. Ther. 1997;19:330–345
  4. Blass JP, Sheu RK-F, Gibson GE. Inherent abnormalities in energy metabolism in Alzheimer disease: interaction with cerebrovascular compromise. Ann. N.Y. Acad. Sci. 2000;903:204–221
  5. Blass JP. Brain metabolism and brain disease: is metabolic deficiency the proximate cause of Alzheimer dementia?. J. Dev. Neurosci. 2001;66:851–856
  6. Gibson GE, Blass JP. Metabolism and neurotransmission. In:  Lajtha A editors. Handbook of Neurochemistry. vol. 3, 2nd ed.:New York: Plenum; 1983;p. 633–651

PII: S0022-510X(02)00320-9

Journal of the Neurological Sciences
Volume 206, Issue 1 , Page 1 , 15 January 2003

Article Tools